Clinical Guides
Trichomoniasis
An India-contextualised, clinically focused guide to recognising, testing and treating Trichomonas vaginalis infection while preventing reinfection and avoiding syndromic overdiagnosis.
MedNext Academy | 15 min read
Trichomoniasis
An India-contextualised, clinically focused guide to recognising, testing and treating Trichomonas vaginalis infection while preventing reinfection and avoiding syndromic overdiagnosis.
Summary
Trichomoniasis is a sexually transmitted urogenital infection caused by the flagellated protozoan Trichomonas vaginalis. It is curable, but it is frequently missed because many infected people have no symptoms and because discharge, dysuria and irritation overlap with several other genital conditions. In women, infection may cause diffuse malodorous or yellow-green vaginal discharge, vulvovaginal soreness, dysuria, dyspareunia and cervical punctate erythema. In men it is often asymptomatic, but urethral discharge, dysuria, urethritis, epididymal discomfort or prostatitis-like symptoms may occur. A strawberry cervix is memorable for examinations but neither common enough nor specific enough to make the diagnosis alone.
Diagnosis is strongest when a nucleic-acid amplification test detects T. vaginalis from a validated specimen. Motile trophozoites on prompt saline wet mount are diagnostic, but microscopy loses sensitivity quickly and a negative wet mount does not exclude infection. Culture and other validated rapid assays have roles where NAAT is unavailable. Vaginal pH is often above 4.5, yet this also occurs in bacterial vaginosis. Assess cervicitis, pelvic inflammatory disease, pregnancy and other STIs rather than treating the discharge colour.
WHO 2024 suggests metronidazole 400 mg or 500 mg orally twice daily for seven days for adults and adolescents, including pregnant patients. Treat current sexual partners concurrently, advise no sexual contact until treatment is complete and symptoms have resolved, and offer HIV, syphilis, gonorrhoea and chlamydia testing according to exposure and national guidance. Persistent infection requires a structured assessment for reinfection, non-adherence, wrong diagnosis and nitroimidazole resistance. This quarantined guide is educational, not a personal prescription, and has been reviewed by the MedNext Clinical Team.
How Common Is It?
Trichomoniasis is the most common non-viral sexually transmitted infection globally. WHO estimated approximately 156 million new infections among people aged 15 to 49 years in 2020. That global model is useful for showing scale, but it must not be presented as a current Indian prevalence estimate. Prevalence varies substantially by sex, age, geography, sexual network, HIV status, symptoms, clinic setting and test method. Studies based on wet-mount microscopy will miss more infections than sensitive molecular testing, while symptomatic STI-clinic samples cannot be extrapolated to the general population.
The observed burden is higher in women than men in many prevalence studies because infection may persist longer, vaginal testing is more established and male diagnostic sensitivity is lower. WHO reports that more than half of infected women may have vaginal discharge, whereas only a minority of infected men have urethritis or discharge. These proportions describe populations, not a diagnostic rule: asymptomatic infection is common in every sex, and symptoms alone cannot confirm the organism. Infection can last for months or longer without treatment, sustaining transmission between partners who may both feel well.
India does not have one laboratory-confirmed national prevalence percentage that can safely be applied to every community or clinic. NACO includes trichomoniasis within vaginal-discharge syndrome and the national STI/RTI service framework, confirming programme relevance. Local antenatal, community and high-risk-population studies use different assays and sampling frames, so an isolated percentage needs its setting and denominator.
The burden includes more than consultations for discharge. Infection is associated with increased HIV acquisition and transmission and with adverse reproductive outcomes, although association does not prove that treatment will reverse every outcome in every population. Public-health practice therefore combines accessible diagnosis and treatment with partner services, condoms, HIV prevention and stigma-free follow-up.
Risk Factors
The necessary exposure is usually sexual contact with an infected partner, particularly vaginal or genital contact without an effective barrier. A current partner can have no symptoms and still transmit infection. Risk rises with a new partner, multiple or overlapping partners, inconsistent condom use, a previous STI, a partner with an STI, and residence in or attendance at a setting with higher background prevalence. These are epidemiological prompts for testing, not moral categories, and none is required before a patient is offered confidential care.
Women with HIV have particular clinical importance because trichomoniasis is associated with genital inflammation and increased HIV shedding, and CDC recommends routine screening for T. vaginalis among women with HIV. Other people may be considered for screening in high-prevalence settings or when individual exposure suggests risk, but universal asymptomatic population screening is not established. Pregnancy does not create the infection, although symptoms and associated pregnancy outcomes make prompt assessment important. Douching and intravaginal products may disrupt the vaginal environment, aggravate symptoms or obscure microscopy; they are not a substitute for prevention.
Reinfection is the most important risk after treatment. If partners are not treated at the same time, intercourse resumes before all courses are complete, or a new exposure occurs, a repeat positive result is more likely to represent transmission than antimicrobial resistance. Incomplete dosing, vomiting, intolerance and use of an inappropriate single-dose regimen in a context where seven-day therapy is recommended also contribute to persistence.
Nitroimidazole resistance exists but should not be assumed from symptoms alone. The patient may instead have bacterial vaginosis, candidiasis, cervicitis, pelvic inflammatory disease, urinary infection, irritant dermatitis or mixed infection. A careful sexual, medicine, pregnancy and treatment history therefore separates acquisition risk, complication risk and apparent treatment failure rather than turning every recurrence into a resistant-organism claim.
Diagnosis
The diagnostic task is to establish T. vaginalis infection at the relevant urogenital site while looking for alternative or coexisting disease. A syndromic label can support immediate care where diagnostics are unavailable, but it is not laboratory proof of trichomoniasis. Obtain specimens before treatment when feasible without delaying urgent management.
History
Ask about onset and change in vaginal or urethral discharge, odour, itch, burning, dysuria, urinary frequency, dyspareunia, lower abdominal pain, fever, bleeding, genital ulcers and testicular or epididymal pain. Record the last menstrual period, pregnancy possibility, postpartum status, contraception, HIV status, previous STIs, recent antibiotics or nitroimidazoles, allergies, liver or neurological disease and self-treatment. Take a private, non-judgemental sexual history covering anatomical sites of exposure, partners, condoms, partner symptoms and possibility of assault or coercion. For recurrence, document the exact regimen, doses missed, vomiting, partner treatment and sex before completion.
Examination
With consent and a chaperone, inspect the vulva, vagina, cervix, urethral meatus and genital skin as indicated. Women may have diffuse erythema, discharge and sometimes punctate cervical haemorrhages; men may have urethral discharge. Examine the abdomen and perform a consented bimanual assessment when pelvic pain suggests PID. Testicular pain or swelling needs scrotal assessment. Ulcers, lymph nodes, pregnancy signs and systemic observations redirect the work-up. A normal examination does not exclude infection.
Investigations
Use a validated NAAT where available, following the assay's approved vaginal, endocervical, urine or male specimen instructions. Saline wet mount can show motile flagellated trophozoites, but must be read promptly and has limited sensitivity. Culture or validated rapid antigen or molecular tests are alternatives. Vaginal pH commonly exceeds 4.5 but is nonspecific. Test for HIV, syphilis, gonorrhoea and chlamydia according to national guidance and exposure; perform pregnancy testing when it changes care. In recurrent disease, do not use NAAT before three weeks after treatment completion because residual nucleic acid can mislead.
Differential Diagnosis
Bacterial vaginosis commonly produces thin homogeneous discharge and fishy odour with vaginal pH above 4.5, but usually less visible inflammation. Amsel criteria or Nugent scoring support BV; motile trichomonads or a specific molecular result support trichomoniasis. The two can coexist. Vulvovaginal candidiasis more often causes intense pruritus, vulval erythema, fissures and thick discharge with pH generally below 4.5; yeast on microscopy or culture must be interpreted with symptoms because colonisation is common. Physiological discharge is not accompanied by marked odour, pain, itch or inflammation.
Cervicitis due to chlamydia or gonorrhoea may cause mucopurulent endocervical discharge, friability, dysuria or postcoital bleeding and is frequently asymptomatic. Mycoplasma genitalium may be relevant in persistent cervicitis or urethritis under specialist pathways. Lower abdominal pain, fever, cervical-motion, uterine or adnexal tenderness raises concern for PID. In men, gonococcal or non-gonococcal urethritis, urinary infection, balanitis and prostatitis can resemble trichomoniasis; purulence or incubation cannot reliably identify the pathogen.
Non-infectious vulvovaginal causes include irritant or allergic contact dermatitis, genitourinary syndrome of menopause, lichen planus, lichen sclerosus, desquamative inflammatory vaginitis and a retained foreign body. Offensive or blood-stained discharge, especially after menopause, requires assessment for a cervical, vaginal or endometrial lesion. Continuous urinary or faecal leakage suggests a fistula rather than vaginitis.
Genital herpes, syphilis, chancroid and traumatic ulcers enter the differential when a lesion is present. Ectopic pregnancy, miscarriage, torsion and other acute pelvic or scrotal disorders must not be hidden beneath an STI label. Finally, persistent symptoms after microbiological cure may reflect post-inflammatory irritation or another diagnosis; repeated metronidazole without re-examination can prolong harm and delay definitive care.
Management
Explain that trichomoniasis is a common, curable STI and that an infection may have been asymptomatic for a prolonged period; a diagnosis cannot date acquisition or prove infidelity. Offer private counselling, answer questions about partners without blame, and document consent. Where a reliable organism-specific result is available, use it. Where laboratory access is limited and immediate treatment is necessary, follow the current NACO enhanced syndromic pathway and explain what the syndrome-based regimen covers and what uncertainty remains.
Give a current recommended oral nitroimidazole regimen after checking pregnancy, allergy, interactions, organ impairment and prior intolerance. Complete every dose even if symptoms settle early. Symptomatic relief and external bland skin care may help irritation, but antiseptic washes, douching and unregulated combination products do not eradicate T. vaginalis. Evaluate and treat PID, epididymitis or another complication through the appropriate pathway rather than assuming uncomplicated vaginitis or urethritis.
Partner management is part of treatment, not an optional add-on. Current partners should receive evaluation and presumptive treatment according to the Indian programme and local law, even if asymptomatic. Advise both patient and partners to avoid sexual contact until all have completed therapy and symptoms have resolved. Condoms reduce future risk but cannot undo an untreated partner reservoir. Offer tests for HIV, syphilis, gonorrhoea and chlamydia, hepatitis services according to exposure, vaccination where indicated, and HIV prevention including PrEP referral when appropriate.
Reassess women approximately three months after treatment where feasible because reinfection is common; if that timing is impossible, retest at the next suitable contact. Persistent symptoms or a repeat positive result require a timeline of adherence, sexual exposure and testing. Exclude reinfection first, verify the diagnosis, and seek specialist or reference-laboratory advice before using high-dose or prolonged resistance regimens. Safety-net pelvic pain, fever, pregnancy symptoms, bleeding and medicine reactions explicitly.
Prescribing Information
WHO 2024 suggests metronidazole 400 mg or 500 mg orally twice daily for seven days for adults and adolescents with trichomoniasis, including pregnant people. This is the clearest global regimen to anchor an educational guide. If adherence to multiple doses is a serious concern, WHO suggests metronidazole 2 g orally once or tinidazole 2 g orally once, except that tinidazole should not be used in pregnancy. CDC 2021 differs by recommending seven-day metronidazole for women and single-dose metronidazole for men. Indian prescribing should follow the current NACO regimen and locally available strength rather than combining recommendations from different jurisdictions.
Common nitroimidazole effects include nausea, metallic taste, abdominal discomfort, headache and dizziness. Review hypersensitivity, severe hepatic disease, significant neurological history and interactions, especially warfarin and other medicines affected by altered anticoagulation. Give alcohol advice from the current Indian product information rather than repeating an unsupported universal interval. Metronidazole has low fetal risk in available human data and symptomatic pregnant patients should be assessed and treated; discuss breastfeeding and any high single dose using current labelling and patient circumstances. Tinidazole has less pregnancy evidence and is avoided during pregnancy in WHO guidance.
Topical metronidazole gel does not reach therapeutic urethral and perivaginal concentrations and is not recommended to cure trichomoniasis. Do not substitute a vaginal antifungal, antibiotic combination or partner's tablets. If vomiting occurs soon after a dose, seek medicine-specific advice rather than automatically doubling it.
For persistent infection without re-exposure, CDC outlines higher-dose, longer nitroimidazole regimens and specialist susceptibility testing. Those regimens are not appropriate for unsupervised online prescribing. Metronidazole resistance occurs in a minority and tinidazole resistance is less frequent, but laboratory access and regimens vary. A clinician should verify adherence and reinfection, obtain culture or reference advice where possible, and check pregnancy and interactions before escalation.
When to Refer
Refer urgently to gynaecology or emergency care when pelvic pain, fever, cervical-motion or adnexal tenderness suggests PID or tubo-ovarian abscess; when pregnancy is accompanied by pain, bleeding, syncope or fluid loss; or when systemic illness makes outpatient treatment unsafe. Acute scrotal pain needs same-day assessment to exclude torsion and manage epididymo-orchitis. A visible genital or cervical lesion, significant unexplained bleeding, retained foreign body or suspected fistula requires directed examination rather than another empirical STI kit.
Refer to a sexual-health, dermatology/venereology or infectious-disease service for persistent NAAT- or culture-confirmed infection after an appropriate completed regimen when reinfection has been reasonably excluded. Specialist input is also appropriate after severe nitroimidazole hypersensitivity, major drug interactions, clinically important liver or neurological disease, repeated intolerance, uncertain pregnancy regimen, or suspected resistance. Reference laboratories may advise susceptibility testing, but availability in India is not uniform and should never be promised.
A recurrent discharge with repeatedly negative T. vaginalis tests warrants gynaecology or vulval-disease review for BV, Candida, cervicitis, dermatosis, inflammatory vaginitis, foreign body or neoplasia. HIV-positive patients with complex coinfection, pregnancy with recurrent infection, and patients needing HIV PrEP or post-exposure services may benefit from integrated specialist care.
Safeguarding referral is required when there is sexual assault, coercion, trafficking, intimate-partner violence or an STI concern in a child, using applicable Indian legal and child-protection procedures. Referral must preserve confidentiality and should not expose the patient to partner violence. If routine diagnostic services are unavailable locally, NACO-linked STI/RTI services or a higher laboratory tier may provide etiological testing and partner support. Send the treatment history, test type, specimen site and timing so the next clinician can interpret a repeat result safely.
Red Flags
Trichomoniasis usually causes local urogenital symptoms, so haemodynamic instability, severe abdominal pain, guarding, persistent vomiting, high fever or altered mental state is not routine infection. In a patient with pelvic pain, cervical-motion, uterine or adnexal tenderness can signal PID; a pelvic mass or severe unilateral pain may represent abscess, torsion or another acute abdomen. Pregnancy with pain, bleeding, dizziness, shoulder-tip pain or syncope requires urgent assessment for ectopic pregnancy. Pregnancy with fluid leakage, contractions or reduced fetal movement follows an obstetric pathway.
Acute unilateral scrotal pain, a high-riding testis, marked swelling or systemic illness requires urgent evaluation because torsion or severe epididymo-orchitis cannot be diagnosed remotely. Visible ulcers, necrosis, rapidly spreading genital inflammation, urinary retention, severe vulval oedema or a painful fluctuant mass are not managed by routine metronidazole alone. Postcoital, intermenstrual or postmenopausal bleeding, a friable cervical mass or blood-stained watery discharge needs assessment for cervical and other genital pathology.
Medicine red flags include facial or tongue swelling, breathing difficulty, widespread blistering rash, jaundice, severe persistent vomiting, confusion, ataxia, new peripheral numbness, seizures, or significant bleeding in a person taking anticoagulants. Stop and seek urgent clinical advice according to severity. Repeated unsupervised nitroimidazole exposure can cause harm and may not treat the actual diagnosis.
Safeguarding signals include disclosure of assault, inability to negotiate sexual safety, reproductive coercion, fear of partner notification, trafficking indicators or symptoms in a child. Provide privacy and follow local protocols without forcing confrontation. Treatment failure is also a safety flag when a validated positive test persists after correct therapy with no sexual re-exposure: do not label the patient non-adherent or prescribe escalating doses without expert assessment.
Indian Clinical Context
NACO's 2024 National Technical Guidelines on STI and RTI are the primary Indian programme reference. Trichomoniasis is addressed within vaginal-discharge and STI/RTI pathways, with enhanced syndromic management used when same-visit etiological testing is not accessible. The practical advantage is immediate treatment and reduced loss to follow-up; the limitation is imperfect specificity. A colour-coded kit or syndrome label may cover several likely organisms, but it does not prove which infection was present and should not substitute for testing in persistent, recurrent, pregnant or atypical disease.
At a peripheral clinic, careful history, abdominal assessment, pregnancy evaluation and red-flag screening remain possible even without NAAT. Prompt wet mount may help when a microscope and trained reader are available, but its sensitivity falls rapidly. District and tertiary services should use validated molecular testing where feasible, particularly after treatment failure or when cervicitis and mixed infection matter. NACO-linked Suraksha Clinics can integrate HIV and syphilis testing, condoms, partner services and referral. Availability varies, so the guide cannot promise one test at every location.
Prescribe generically and verify current NACO dosing, CDSCO-authorised product information, local stock, pregnancy status, breastfeeding, allergies and interactions. Do not import US expedited-partner-therapy law into India. Partner care must follow Indian programme procedures, preserve consent and consider violence risk. Counselling should be available in the patient's preferred language and explain that asymptomatic carriage means diagnosis cannot establish when or from whom infection was acquired.
India-specific antimicrobial-resistance surveillance for T. vaginalis is limited compared with gonorrhoea surveillance. Most repeat infection is more plausibly reinfection or incomplete therapy than proven resistance. Suspected resistance therefore needs documented treatment and exposure history, a valid repeat test at the correct interval, and specialist or reference support rather than a confident local resistance label.
NMC Competency Mapping
The NMC Competency Based Medical Education Curriculum 2024 explicitly includes Trichomonas vaginalis in OG22.2, which covers the aetiology, clinical characteristics, diagnosis, investigations, genital hygiene, common-cause management and syndromic management of vaginal discharge. OG22.1 supplies the comparison with physiological discharge. The learner should understand that trichomoniasis is a protozoal STI, distinguish infection from a symptom label and avoid diagnosing it from a green discharge or strawberry cervix alone.
Diagnostic competence includes a private sexual and reproductive history, consented examination, recognition of vaginitis, cervicitis and PID, and selection of a validated test. Learners should know the characteristic motile trophozoite on immediate saline wet mount, the limitations of microscopy, the higher sensitivity of NAAT and the nonspecific nature of a raised pH. MI8.1 and MI8.2 support organism and laboratory principles, while MI8.3 addresses the concept and utility of syndromic STI management.
DR10.10 and OG35.5 support case-based diagnosis and management of vaginal discharge. A safe management answer gives a current generic regimen, checks pregnancy and interactions, treats partners, advises abstinence until treatment is completed, offers other STI tests and arranges retesting or review. It separates a routine recurrence from suspected resistance and does not improvise a high-dose regimen.
At Show How level, a learner should explain specimen collection, counsel without stigma, protect confidentiality, assess partner safety and provide a precise safety net. Men with urethritis must not be omitted merely because the named obstetric competency concerns discharge. Formal teaching should reconcile these mappings with the institution's current approved ledger; this guide provides learning support and does not certify independent genital examination, prescribing or clinical review completion.
Key Exam Pearls for NEET PG
Trichomonas vaginalis is a flagellated protozoan with a trophozoite stage and no cyst stage. It infects the urogenital tract and is transmitted predominantly by sexual contact. The classic microscopy answer is a motile, jerky trophozoite on a fresh saline wet mount. The sample must be examined promptly because motility and sensitivity fall with delay. NAAT is more sensitive, so a negative wet mount does not exclude infection. Culture is an alternative and can assist recurrent-infection assessment.
In women, remember diffuse malodorous or yellow-green discharge, vulvovaginal irritation, dysuria, dyspareunia and sometimes a strawberry cervix. In men, asymptomatic infection is common; urethritis and discharge can occur. Vaginal pH is often above 4.5, as in BV, whereas uncomplicated Candida usually retains a lower pH. Do not use colour, froth or punctate erythema as a standalone diagnostic criterion. Mixed infection and cervicitis are possible.
The current WHO anchor is metronidazole 400 mg or 500 mg orally twice daily for seven days for adults and adolescents, including pregnancy. Single 2 g metronidazole or tinidazole regimens are alternatives when multi-dose adherence is a serious concern; tinidazole is avoided in pregnancy. CDC sex-specific regimens differ, demonstrating why an exam stem's named guideline and jurisdiction matter. Topical metronidazole gel is inadequate for trichomoniasis.
Treat partners concurrently and avoid sex until all treatment is complete and symptoms resolve. Retest women around three months because reinfection is common. For persistent disease, distinguish reinfection, missed doses and wrong diagnosis from resistance; do not perform NAAT earlier than three weeks after treatment completion. Always add HIV and other STI assessment, pregnancy safety, PID red flags and non-stigmatising counselling to a complete answer.
Frequently Asked Questions
Can trichomoniasis be present when neither partner has any symptoms?
Yes. T. vaginalis frequently causes no symptoms, particularly in men, and infection can persist long enough for transmission between people who feel well. A positive result cannot determine exactly when infection was acquired or prove recent infidelity. Current partners still need evaluation and treatment because an asymptomatic untreated partner can cause reinfection. Testing should use a validated assay at the exposed anatomical site rather than relying on absence of discharge or irritation.
Why is a negative wet mount insufficient to rule out trichomoniasis?
Wet-mount microscopy depends on enough living organisms being present and on examining the sample promptly while trophozoites remain motile. Its sensitivity is substantially lower than that of a validated NAAT and falls as the specimen waits. Seeing motile trophozoites is useful positive evidence, but a negative slide in a symptomatic or exposed patient should lead to NAAT, culture or another validated test where available rather than confident exclusion.
Do sexual partners require treatment at the same time for trichomoniasis?
Yes. Concurrent partner treatment is central because repeat infection commonly comes from an untreated partner. Current partners should be evaluated and treated under the applicable Indian programme and local clinical pathway, even if they report no symptoms. Sexual contact should stop until everyone has completed the prescribed course and symptoms have resolved. Partner communication must be confidential, non-coercive and adapted if notification could trigger violence or other harm.
Does persistent trichomoniasis automatically mean metronidazole resistance?
No. Reinfection, incomplete dosing, vomiting, sex before partner treatment, an early misleading NAAT, or a different diagnosis are more common explanations. Confirm the original and repeat test, specimen site and timing, document the exact regimen, and exclude re-exposure. If validated infection persists after appropriate therapy without re-exposure, specialist or reference-laboratory advice is appropriate because resistance regimens use higher doses or longer courses and require individual safety assessment.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic